Editas Medicine opened lower at $2.33, compared with its previous close of $2.38. In the last trading session, the stock traded between $2.12 and $2.33. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Editas Medicine is now worth
$ 5.59
Resulting in a loss of
$ 94.41 (94.41%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.25 (-10.29%)
Day High
$2.33
Day Low
$2.12
Day Open
$2.33
Prev Close
$2.38
Volume
36,12,469
1W Return
-21.94%
1M Return
-21.94%
3M Return
-27.75%
6M Return
-30.23%
1Y Return
-19.74%
Fundamentals
Market Cap ($ Mn)
330
PE Ratio
-
PB Ratio
4.59
PEG Ratio
-
ROE
-311.86%
ROCE
-92.18%
EPS (TTM)
$-0.15
Investment Returns
1 Week
-21.94%
1 Month
-21.94%
3 Months
-27.75%
6 Months
-30.23%
9 Months
20.62%
Financials
Quarterly
All values in $ Mn
4.7
Mar 25
3.6
Jun 25
7.5
Sep 25
24.7
Dec 25
11.9
Jun 26
10.4
Sep 26
Updates
8Oct
Editas Medicine gets Australia approval for EDIT-401 clinical trial
Editas Medicine received HREC and TGA approval for its Phase 1/2 Strive trial of EDIT-401 in Australia. Preclinical data showed ~90% mean reduction in LDL-C, Lp(a), and ApoB in non-human primates. New data indicates the ~90% LDL-C reduction was maintained over 10 months in ongoing studies. The company submitted for review in New Zealand, allowing potential enrollment from both countries.
1mo ago
1Sep
Editas Medicine files prospectus for $400m mixed shelf offering
Editas Medicine files SEC prospectus for mixed shelf offering. Maximum aggregate offering size set at $400 million. Filing allows flexibility in issuing various securities types. No immediate issuance schedule or final terms disclosed.
2mo ago
6Aug
Editas Medicine Q2 Results: Sales Surge 232.59% YoY To $11.900 Million
Editas Medicine delivered a strong Q2 performance, with EPS of $(0.15) beating the $(0.27) estimate. Sales jumped to $11.900 million, up 232.59% YoY, far exceeding the $2.800 million forecast. Losses narrowed significantly compared to the prior year.
